6-K filed Nov 12, 2026 at 07:45 ET
Ascendis Pharma reported Q3 2026 product revenue of EUR 366M (+89% YoY), driven by YORVIPATH (EUR 291M, +103% YoY), SKYTROFA (EUR 59M), and YUVIWEL (EUR 16M). The company achieved an operating profit of EUR 125M (34% margin) compared to EUR 11M a year ago, and net profit of EUR 74M (EUR 1.08 diluted EPS) vs a net loss of EUR 61M. The company received positive CHMP and COMP opinions for TransCon CNP in the EU, with a final EC decision expected in Q4 2026.